News | November 07, 2025
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
Speakers are: Dr. Alok Khullar, Senior Technology Leader, Pidilite Industries; Dr. Kamlesh Pai Fondekar, Head - R&D, Godrej Agrovet; Dr. Hiten Mehta, Head - R&D (Chlor-Alkali), Aditya Birla Chemicals; Dr. Anil Kumar Soni, Head - Application Development, R&D, Clariant Chemicals India; Dr. Rupak Paul, Deputy General Manager – Formulation, Rallis India; Dr. Manish M. Khandagale, Senior Field Application Specialist, Revvity Signals; and Pravin Prashant, Executive Editor, Indian Pharma Post
From material selection to cooling tower management, every small decision affects long-term equipment reliability
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
This approval marks a significant milestone in women’s health, introducing Bayer’s first hormone-free treatment for menopause-related symptoms
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
Partnership combines MilliporeSigma’s chemistry and organoid expertise with Promega’s assay technologies
With milestone-linked funding of Rs. 5–25 crore per project (and up to Rs. 50 crore in exceptional cases), the Mission will support projects that bring impactful MedTech solutions to market
Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
Subscribe To Our Newsletter & Stay Updated
